A Phase 1b Randomised, Open-Label, Dose Comparison Study Examining the Safety, Tolerability, and Efficacy of KB001 Antibody Mediated Oral Clearance of Porphyromonas gingivalis in Periodontitis (2023)
- Grant type:
- Beyond Drug Development
- Researchers:
-
-
Head of School
School of DentistryFaculty of Health and Behavioural Sciences -
Clinical Associate Professor
School of DentistryFaculty of Health and Behavioural Sciences
-
- Funded by:
- Beyond Drug Development Pty Ltd
